Clinical trial
Interleukin-2 in Treating Patients With Relapsed or Refractory Acute Myelogenous…
NCT00003148 · European Organisation for Research and Treatment of Cancer - EORTC, Other · Completed
Key facts
| NCT number | NCT00003148 |
|---|---|
| Title | Interleukin-2 in Treating Patients With Relapsed or Refractory Acute Myelogenous Leukemia |
| Official title | Phase II Study of the Efficacy of rH Interleukin-2 in Patients With Slowly Progressing Acute Myelogenous Leukemia (AML) and With Limited Bone Marrow Blastosis After Autologous Stem Cell Transplantation or Chemotherapy |
| Lead sponsor | European Organisation for Research and Treatment of Cancer - EORTC, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Biological |
| Interventions | aldesleukin |
| Enrollment | 86 |
| Start date | Oct 1, 1997 |
| Primary completion | Apr 1, 2001 |
| First posted | Apr 23, 2004 |
| Last update posted | Jul 2, 2012 |
| Countries | Austria, Belgium, Croatia, France, Italy, Netherlands |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: